Genome writing company Replay has raised $55 million in a seed fundraising round.
Replay has a portfolio of gene writing technologies that include an algorithm for rewriting proteins, a genome writing platform, immune silencing technology and technology that facilitates gene delivery.
"Our ability to write and deliver big DNA has the potential to disrupt many areas of genomic medicine. We have the right team, corporate structure, portfolio of technology platforms and financial backing to build an enduring company that shapes the future of the industry," said Replay co-founder and CEO Lachlan MacKinnon in a July 25 press release.
This seed funding round was led by Kolhberg Kravis Roberts and OMX Ventures.